20:04 , Jan 18, 2019 |  BC Week In Review  |  Clinical News

China approves Linzess for IBS-C

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said China's National Medical Products Administration approved Linzess linaclotide to treat irritable bowel syndrome with constipation (IBS-C). The company expects to launch the guanylate cyclase C (GCC; GUCY2C) agonist in China...
00:53 , Jan 18, 2019 |  BC Week In Review  |  Company News

Tribe, Allergan appeal sovereign immunity patent case to Supreme Court

The Saint Regis Mohawk Tribe and Allergan plc (NYSE:AGN) asked the U.S. Supreme Court to review a federal court's ruling that a sovereign entity cannot assert immunity to shield a patent from inter partes review...
23:11 , Jan 15, 2019 |  BC Extra  |  Company News

Tribe, Allergan appeal sovereign immunity patent case to Supreme Court

The Saint Regis Mohawk Tribe and Allergan plc (NYSE:AGN) asked the U.S. Supreme Court to review a federal court's ruling that a sovereign entity cannot assert immunity to shield a patent from inter partes review...
01:06 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Heart transplant rejection; graft rejection Mouse studies suggest inhibiting CORO1A or its downstream mediator PDE-4 could help treat heart transplant and skin graft rejection. In a mouse model of heart transplantation, systemic CORO1A knockout...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
23:55 , Jan 2, 2019 |  BC Extra  |  Politics & Policy

Part D beneficiaries hit hardest under 2019 price hikes

Drug price increases announced beginning Jan. 1 will disproportionately affect Medicare Part D beneficiaries, reinforcing a practice the Trump administration has sought to curb. Data from Evercore ISI Research on 13 pharmaceutical and biotech companies...
01:15 , Dec 22, 2018 |  BioCentury  |  Product Development

A year of digital progress at Novartis

Novartis AG Chief Digital Officer Bertrand Bodson is capping off his inaugural year with the pharma’s first approval of a digital therapeutic and 10 deals under his belt to integrate new technologies throughout the company....
20:43 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Dec. 14, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507). The...